Welcome to our dedicated page for Virpax Pharmaceuticals news (Ticker: VRPX), a resource for investors and traders seeking the latest updates and insights on Virpax Pharmaceuticals stock.
Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) is a preclinical-stage pharmaceutical company focused on non-opioid, non-addictive pain management and central nervous system (CNS) disorders, using novel drug delivery technologies. The Virpax news feed on Stock Titan highlights company announcements that describe progress across its prescription and nonprescription product candidates and capital markets activity.
News items commonly cover Virpax’s pipeline developments, such as preclinical dose range finding studies and animal model data for Probudur™, its long-acting liposomal bupivacaine formulation for post-operative pain. Releases also discuss updates on Envelta™ (NES100), an intranasal molecular envelope enkephalin formulation for acute and chronic pain, and NobrXiol™, an intranasal cannabidiol (CBD) candidate for rare pediatric epilepsy that uses Molecular Envelope Technology (MET) to target delivery to the brain.
Investors can follow announcements about Virpax’s collaborations and CRADAs with organizations such as the National Institutes of Health, the Department of Defense, and the U.S. Army Institute of Surgical Research, which has evaluated Probudur in combat care-related pain models. The news stream also includes updates on MET-related studies conducted by partners like Nanomerics, including human safety data for MET-based formulations.
In addition, Virpax issues news regarding financing transactions, including public offerings of common stock and pre-funded warrants, and corporate actions such as reverse stock splits intended to support continued listing on the Nasdaq Capital Market. The company also reports on exploratory work using MET or similar technology for intranasal mRNA COVID vaccine delivery and on efforts to seek partners for nonprescription candidates such as AnQlar and Epoladerm.
By monitoring this page, readers can review Virpax’s official press releases on its research progress, regulatory interactions, collaborations, and capital markets events in one place.
Nanomerics Ltd announced a milestone payment following the expansion of its anti-viral spray license for AnQlar™ to Virpax Pharmaceuticals (NASDAQ:VRPX). The agreement now includes worldwide rights, and the deal features an upfront payment with future revenue sharing. This funding will support Nanomerics' growth and clinical programs. CEO expressed satisfaction with the partnership aimed at developing AnQlar™ as a nasal spray to combat respiratory viruses, including SARS-CoV-2 variants.
Virpax Pharmaceuticals (NASDAQ: VRPX) has expanded its exclusive licensing agreement for AnQlar™ with Nanomerics Ltd., securing worldwide rights for development and commercialization. AnQlar has shown antiviral activity against SARS-CoV-2 and influenza in preclinical studies, inhibiting viral replication without adverse effects. Virpax aims for Investigational New Drug (IND) studies completion by Q4 2022 and plans to pursue a nonprescription drug approval pathway. Enhanced global rights are expected to strengthen strategic opportunities for AnQlar.
Virpax Pharmaceuticals (NASDAQ: VRPX) has gained media attention for its potential solutions to the opioid epidemic and COVID-19. The focus is on several non-addictive drug candidates: AnQlar™, an intranasal antiviral; Epoladerm™, targeting osteoarthritis pain; Probudur™, a long-acting anesthetic for post-surgical pain; and Envelta™, for cancer-related pain. CEO Anthony Mack shared insights on the opioid crisis, while Dr. Sheila Mathias, Chief Scientific Officer, discussed the company's product portfolio in interviews.
Virpax Pharmaceuticals (NASDAQ: VRPX) reported promising preclinical data on Envelta (NES100), an intranasal enkephalin spray designed for pain management in acute and chronic cases. Studies indicate Envelta is well-tolerated with no adverse findings in toxicity assessments conducted by the NIH. The company is focused on submitting an IND to the FDA to initiate Phase 1 trials, aiming to support its potential as a non-addictive treatment for cancer pain and PTSD.
Virpax Pharmaceuticals (NASDAQ: VRPX) has selected Altasciences to conduct a first-in-human study of Epoladerm™ for chronic knee pain due to osteoarthritis. This innovative treatment utilizes a pre-filled device for a convenient topical spray application. Set to begin in Q2 2022 at Altasciences’ Montreal facility, the study aims to support the FDA's 505(b)(2) approval pathway. Altasciences, experienced in clinical trials, is committed to advancing this analgesic therapy towards regulatory approval, enhancing patient care through its cutting-edge technology.
Virpax Pharmaceuticals (NASDAQ: VRPX) announced positive results from four preclinical dermal safety studies for its investigational product, Epoladerm (diclofenac epolamine), aimed at managing osteoarthritis knee pain. Conducted by Charles River Laboratories, these studies indicated that Epoladerm was well-tolerated with no serious adverse findings, including skin irritation or sensitization. The successful outcomes support the company’s upcoming Investigational New Drug Application, paving the way for first-in-human trials.
Virpax Pharmaceuticals will present virtually at the H.C. Wainwright BioConnect Virtual Conference from January 10 to January 13, starting at 7:00 a.m. ET. CEO Anthony Mack will lead the presentation, with one-on-one meetings available on January 10 and 11. Participants can watch the presentation on-demand daily until 7:00 p.m. ET and access a replay for 90 days on the company’s website. Virpax focuses on non-addictive pain management and neurological disorders, aiming for FDA approval of several innovative drug delivery systems.
Virpax Pharmaceuticals (NASDAQ: VRPX) has made notable strides in its product pipeline as of 2021. The company anticipates starting initial human trials for Epoladerm in Q2 2022. Key advancements include the development of AnQlar, an OTC antiviral candidate, and VRP324, a CBD formulation for epilepsy. Additionally, Virpax appointed new board members and raised approximately $58 million from IPOs, enhancing its R&D funding. Epoladerm’s toxicology study showed it was well-tolerated in minipigs. The company intends to conduct Phase 1 studies for Epoladerm in Canada soon.
Virpax Pharmaceuticals (NASDAQ: VRPX) has entered into a clinical trial agreement with Altasciences for a First in Human study of Epoladerm™, targeting pain associated with osteoarthritis of the knee. The trial, set to commence in Canada, aims to enroll its first patient by Q2 2022. Epoladerm™ is a topical spray film designed to provide a non-addictive solution for chronic pain. The data generated will support regulatory filings for FDA approval under the 505(b)(2) pathway, enhancing Virpax's portfolio for non-addictive pain management.
Virpax Pharmaceuticals (NASDAQ: VRPX) announced successful toxicology and pharmacokinetic study results for Epoladerm™, aimed at managing knee osteoarthritis pain. Conducted by Charles River Laboratories, the study demonstrated that Epoladerm was well-tolerated, with no adverse effects observed in minipigs. Plasma levels confirmed effective transdermal absorption, peaking at four hours post-dose and remaining detectable after 24 hours. These findings are expected to bolster the Company’s IND filing, paving the way for upcoming first-in-human clinical trials.